文献速递流行病学与生物统计临床试验与 GCP真实世界研究与卫生经济

CAR-T细胞治疗后非复发死亡的系统综述与荟萃分析

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.
PubMed 文献 · Nat Med · 2024-07-08

该系统综述与荟萃分析检索MEDLINE、Embase和CINAHL(Cochrane)截至2024年3月的文献,纳入18项临床试验和28项真实世界研究共7604例接受CAR-T细胞治疗的淋巴瘤和多发性骨髓瘤患者,采用随机效应模型分析非复发死亡(NRM)点估计值。NRM点估计值因疾病类型而异,套细胞淋巴瘤最高(10.6%),其次为多发性骨髓瘤(8.0%)、大B细胞淋巴瘤(6.1%)和惰性淋巴瘤(5.7%)。574例非复发死亡中超过半数归因于感染(50.9%)。

要点

  • 套细胞淋巴瘤患者NRM点估计值最高,为10.6%。
  • 574例非复发死亡中感染占50.9%,其他恶性肿瘤占7.8%,心血管/呼吸事件占7.3%。
  • CAR-T细胞特异性副作用(ICANS/神经毒性、细胞因子释放综合征和噬血细胞性淋巴组织细胞增多症)合计仅占非复发死亡的11.5%。

核心结论

  • 研究结果强调CAR-T细胞治疗后感染性并发症的至关重要性,并支持全面报告NRM,包括具体原因和长期结局。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和CINAHL(Cochrane)截至2024年3月的文献,纳入淋巴瘤和多发性骨髓瘤患者接受CAR-T细胞治疗后非复发死亡(NRM)的报告。
  • 共纳入18项临床试验和28项真实世界研究,合计7604例患者。
  • 提取死亡原因和数量后,采用随机效应模型分析NRM点估计值。

主要发现

  • NRM点估计值因疾病类型而异,套细胞淋巴瘤患者最高(10.6%),其次为多发性骨髓瘤(8.0%)、大B细胞淋巴瘤(6.1%)和惰性淋巴瘤(5.7%)。
  • 针对大B细胞淋巴瘤和多发性骨髓瘤的疾病特异性荟萃回归模型显示,阿基仑赛(axicabtagene ciloleucel)和西达基奥仑赛(ciltacabtagene autoleucel)分别与NRM点估计值升高独立相关。
  • 574例报告的非复发死亡中,超过半数归因于感染(50.9%),其次为其他恶性肿瘤(7.8%)和心血管/呼吸事件(7.3%)。
  • CAR-T细胞特异性副作用——免疫效应细胞相关神经毒性综合征/神经毒性、细胞因子释放综合征和噬血细胞性淋巴组织细胞增多症——合计仅占非复发死亡的11.5%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although chimeric antigen receptor (CAR) T cell therapy represents a transformative immunotherapy, it is also associated with distinct toxicities that contribute to morbidity and mortality. In this systematic review and meta-analysis, we searched MEDLINE, Embase and CINAHL (Cochrane) for reports of nonrelapse mortality (NRM) after CAR T cell therapy in lymphoma and multiple myeloma up to March 2024. After extraction of causes and numbers of death, we analyzed NRM point estimates using random-effect models. We identified 7,604 patients across 18 clinical trials and 28 real-world studies. NRM point estimates varied across disease entities and were highest in patients with mantle-cell lymphoma (10.6%), followed by multiple myeloma (8.0%), large B cell lymphoma (6.1%) and indolent lymphoma (5.7%). Entity-specific meta-regression models for large B cell lymphoma and multiple myeloma revealed that axicabtagene ciloleucel and ciltacabtagene autoleucel were independently associated with increased NRM point estimates, respectively. Of 574 reported nonrelapse deaths, over half were attributed to infections (50.9%), followed by other malignancies (7.8%) and cardiovascular/respiratory events (7.3%). Conversely, the CAR T cell-specific side effects, immune effector cell-associated neurotoxicity syndrome/neurotoxicity, cytokine release syndrome and hemophagocytic lymphohistiocytosis, represented only a minority of nonrelapse deaths (cumulatively 11.5%). Our findings underline the critical importance of infectious complications after CAR T cell therapy and support the comprehensive reporting of NRM, including specific causes and long-term outcomes.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Cordas Dos Santos DM, Tix T, Shouval R, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024. PMID: 38977912. doi:10.1038/s41591-024-03084-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。